Back to Rankings

MASI

MasimoC
Nasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
View Chart

AI scenario view

RankAlpha Sentiment Codex
B+
Bull case
32%
Probability
Target price
$180.00
+0.7% vs current
Most likely
B
Base case
53%
Probability
Target price
$179.40
+0.4% vs current
B-
Bear case
15%
Probability
Target price
$145.00
-18.9% vs current

AI sentiment snapshot

Latest data as of 2026-04-15
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+46.3
Score

AI commentary

Sentiment is mildly positive but still best framed as a cautious monitoring view. The deterministic prior is positive, yet evidence quality is only moderate and uncertainty is elevated because MASI is now mostly a merger-spread security with limited upside to $180 and meaningful downside if the transaction slips or breaks.

RankAlpha Sentiment Codex - 2026-04-15
Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact
standard
Confidence
-

AI events

2026-05-01eventMay 1, 2026 stockholder vote is the next hard catalystMedium impact

Masimo’s definitive merger proxy schedules the special meeting for May 1, 2026 at 10:00 a.m. Pacific Time, and the board recommends voting for the merger agreement proposal, making vote approval the clearest near-term event for the stock. [#DEFM14A-2026-04-01]

2026-05-01catalystSpread can compress modestly toward $180 cash consideration into the voteMedium impact

Masimo shares closed at $178.39 on 2026-04-14 versus Danaher’s agreed $180.00 per-share cash price, so remaining near-term upside is mostly limited to merger-spread compression if no new deal friction emerges before the special meeting. [#8-K-2026-02-17] [#DEFM14A-2026-04-01]

2026-09-30eventSecond-half 2026 closing still depends on regulatory clearancesMedium impact

Masimo’s 10-K and merger communications say the transaction is expected to close in the second half of 2026, subject to customary closing conditions including stockholder approval and required regulatory approvals, so timing of clearance remains the main remaining value unlock after the vote. [#10-K-2026-02-27] [#PR-2026-02-17]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology